High Doses of Botulinum Toxin Type A for the Treatment of Post-Stroke Spasticity: Rationale for a Real Benefit for the Patients.
Andrea SantamatoPublished in: Toxins (2022)
In the past few years, there was a great interest in the use of higher doses of botulinum toxin type A, especially in case of upper and lower limb severe spasticity. To date, only one prospective, non-randomized, single-arm, multicenter, open-label, dose-titration study with the employment of incobotulinum toxin up to 800 U has been published, and the authors investigated safety and tolerability. Other researches showed efficacy in spasticity reduction, but there is a lack of evidence about the reasons to use high doses of botulinum toxin. This short communication highlights the benefits of higher doses for subjects with upper and lower limb spasticity.
Keyphrases
- botulinum toxin
- lower limb
- open label
- double blind
- clinical trial
- end stage renal disease
- phase ii
- phase iii
- ejection fraction
- placebo controlled
- newly diagnosed
- escherichia coli
- chronic kidney disease
- phase ii study
- peritoneal dialysis
- study protocol
- systematic review
- randomized controlled trial
- spinal cord injury
- cross sectional
- mental health
- radiation therapy
- mental illness
- high resolution
- rectal cancer
- atomic force microscopy
- meta analyses